In metastatic breast cancers, the mutational landscape is even greater than in primary tumors, evident in driver genes including TP53, AKT1, ESR1, GATA3, NF1; moreover, greater clonal diversity is evident (Bertucci et al., 2019), reflecting greater complexity within the TME. This evidence concerns the gene ESR1 and breast carcinoma.